Leading AI solution for prostate cancer pathway optimization

 

Advancing the prostate cancer pathway with AI to support physicians, reduce costs, and deliver better care.

%

SENSITIVITY

%

SPECIFICITY

Piâ„¢ matches the accuracy of expert radiologists

The results of a major collaborative research study with 8 UK NHS hospitals, PAIR-1, have been published in the leading journal European Radiology. This study is a landmark in the development and validation of AI for prostate cancer, showing for the first time that Pi™ operates at the level of expert radiologists working in multi-disciplinary teams, across real-world, multi-centre data encompassing different MRI scanner vendors, models and field strengths.This found that Pi™ has outstanding accuracy to detect clinically significant prostate cancer on representative, held-out validation data, with 95% sensitivity and 67% specificity. This high performance allows Pi™ to be used to help find more cancers, rule out patients who do not need further investigations, and save resources and time

Full paper in European Radiology

What clinicians say

‘Pi can identify the most clinically significant cancers and essentially allow me to offer a same day pathway to those patients. MRi in the morning, biopsy in the afternoon

 

Dr Oliver Hulson

Consultant Interventional Radiologist

St James University Hospital Leeds

Trusted by our partners

Latest News

Upcoming conferences

Find out more at these events:

Get in touch, book a demo

To find out more, please contact us via this form